Value & Access Policy Director, Association of the British Pharmaceutical Industry (ABPI)
Paul has worked in the healthcare, local government and pharmaceutical sectors for over 30 years. He began his career in the NHS as a researcher and then held a number of management posts before working on a wide range of UK and international management consultancy assignments at PriceWaterhouseCoopers. After moving to Roche, he led work on national reimbursement of medicines, health economics, strategic pricing and market access.
Paul’s policy work at the ABPI over the last ten years includes all aspects of medicines evaluation, health technology assessment, pricing and reimbursement, market access, the Cancer Drugs Fund, Innovative Medicines Fund, biosimilar medicines, EAMS, ILAP and the Accelerated Access Collaborative. He has led the work on shaping and evolving value, access and uptake policy for the pharmaceutical industry in the UK across the last four Voluntary Scheme negotiations, including the current Voluntary Scheme for Branded Medicines Pricing and Access.
He has a Ph.D in healthcare information systems and is a Member of the British Computer Society and a Chartered Information Technology Professional.
Stevenage Bioscience Catalyst30 November 2023